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Abstract
Background and Aims—Chronic hepatitis C virus (HCV)-related complications have 
increased over the past decade.
Methods—We used join-point regression modeling to investigate trends in these complications 
from 2006–2015, and the impact of demographics on these trends. Using data from the Chronic 
Hepatitis Cohort Study (CHeCS), we identified points at which the trend significantly changed, 
and estimated the annual percent change (APC) in rates of cirrhosis, decompensated cirrhosis, and 
all-cause mortality, adjusted by race, sex, and age.
Results—Among 11,167 adults with chronic HCV infection, prevalence of cirrhosis increased 
from 20.8% to 27.6% from 2006 to 2015 with adjusted annual percentage change (aAPC) of 1.2 
(p<0.01). Although incidence of all-cause mortality increased from 1.8% in 2006 to 2.9% in 2015, 
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a join-point was identified at 2010, with aAPCs of 9.6 before (2006<2010; p<0.01) and −5.2 after 
(2010≤2015; p<0.01), indicating a decrease in mortality from 2010 and onward. Likewise, 
although overall prevalence of decompensated cirrhosis increased from 9.3% in 2006 to 10.4% in 
2015, this increase was confined to patients 60 or older (aAPC=1.5; p=0.023). Asian American 
and Black/African American patients demonstrated significantly higher rates of cirrhosis than 
White patients, while older patients and men demonstrated higher rates of cirrhosis and mortality.
Conclusions—Although cirrhosis and mortality among HCV-infected patients in the US have 
increased in the past decade, the mortality has decreased in recent years.
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INTRODUCTION
As many as 65–75% of the estimated 3.5 million hepatitis C virus (HCV)-infected 
Americans are unaware of their infection status and have not received necessary care and 
treatment (1, 2), and remain at high risk for progression to cirrhosis (3), liver failure, and 
hepatocellular carcinoma (2, 4–6). Although rates of new HCV infections have declined 
since a peak in the 1990s (7), overall prevalence has increased as patients discover their 
infection status. Given that individuals born between 1945 and 1965 represent roughly 75% 
of all US HCV cases, epidemiologists have anticipated a rapid upsurge of HCV-related liver 
disease and cirrhosis as this birth cohort ages (8). Moreover, although HCV 
disproportionately affects men and African Americans(9), changes in rates of these 
complications in these demographics have not been well-studied.
This rising burden of HCV-related complications is now being realized. A recent study of 
predominantly male US veterans (N>47,000) showed that the prevalence of cirrhosis 
increased from 9% in 1996 to 18.5% in 2006; decompensated cirrhosis increased from 5% to 
11% over this same period(10). Similarly, a recent general population study using NHANES 
data found that HCV patients demonstrated increasing prevalence of cirrhosis, from 6.6% (in 
1988–1994) to 17.0% (2007–2012)(11). This latter study was limited to a small sample 
(n=725). We sought to determine how the actual trends of cirrhosis and other complications 
have changed over the past decade, and whether race, sex and age impact these trends.
The Chronic Hepatitis Cohort Study (CHeCS) includes over 11,000 HCV patients receiving 
care at one of four large health systems. Because CHeCS comprises a geographically- and 
racially-diverse sample of patients receiving routine clinical care, it is broadly generalizable 
to HCV patients throughout the US (12). We applied join-point modeling to comprehensive 
medical record data to investigate the dynamics of trends of cirrhosis, decompensated 
cirrhosis, and mortality among HCV patients from 2006 to 2015.
METHODS
CHeCS includes patients ≥18 years old who received services on or after January 1, 2006 at 
one of four health care systems—Henry Ford Health System; Geisinger Health System; 
Lu et al. Page 2
Liver Int. Author manuscript; available in PMC 2019 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Kaiser Permanente Northwest; and Kaiser Permanente Hawai’i. The study follows all 
guidelines of the US Department of Health and Human Services regarding the protection of 
human subjects; our protocol was approved and renewed annually by the Institutional 
Review Boards of Henry Ford Health System, Geisinger Health System; Kaiser Permanente 
Northwest; and Kaiser Permanente Hawai’i. Due to the de-identified nature of this 
observational study, requirements for written informed consent were waived.
CHeCS methods have been described (12, 13). Briefly, CHeCS patients are identified 
electronically using a combination of laboratory and ICD9-based criteria. Chronic HCV 
infection is confirmed through chart abstraction (12). For each data collection cycle, a 
random sample of new patients is added to the cohort, while existing patients continue to be 
followed. In the present analysis, we examined annual prevalence of cirrhosis and 
decompensated cirrhosis, and incidence of all-cause mortality, for the 2006–2015 period. 
Patients were included in the sample if they had been diagnosed prior to or during the given 
year, and their last encounter was during or after the given year. HBV/HCV co-infected 
patients were excluded; HIV/HCV co-infected patients were included in analyses.
Our classification of decompensated cirrhosis is based on a statistically rigorous 
classification and regression tree (CART) model that was validated against data from chart 
abstraction. This method classifies a cirrhotic patient to be decompensated cirrhosis if there 
was at least one of ICD9 codes for decompensation-related conditions, yielded validated 
AUROC of 92% and PPV of 85% (14).
Due to the observational nature of this study, availability of cirrhosis data varied. Roughly 
20% of our sample had liver biopsy data; 60% had laboratory data for calculation of FIB4. 
To overcome this variation, we implemented a hierarchical classification algorithm to 
identify cirrhosis: 1) decompensated cirrhosis identified using the CART model; 2) “F4” 
liver biopsy; 3) FIB4>5.88; 4) presence of ICD9/10 diagnosis codes for cirrhosis in the 
medical record. CHeCS has previously validated the use of the Fibrosis-4 (FIB4) serum-
based biomarker in HCV patients; we found that a FIB4 score >5.88, calculated from routine 
laboratory results, accurately classifies cirrhosis (Metavir fibrosis stage F4; area under the 
receiver operator characteristic curve [AUROC]=85% and positive predictive value 
[PPV]=82%)(15). Decompensated cirrhosis was determined using a similar approach. 
Cirrhosis and decompensated cirrhosis were assumed to persist unless records indicated 
receipt of a liver transplant.
Statistical Analysis
Outcomes of interest included prevalence of cirrhosis and decompensated cirrhosis, as well 
as incidence of all-cause mortality (based on our work showing that liver-related mortality is 
under-reported in routine care settings(16)). Covariates of interest included: age during the 
given year (categorized as <40, 40<50, 50<60, and ≥60); sex; and race (categorized as 
Black/African American, Asian American/Pacific Islander [AAPI], White, and Other/
Unknown). Age was used instead of birth cohort in order to assess the effect of aging within 
the cohort.
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Summary statistics are presented as percentages (for categorical variables) and mean/
standard deviations (for continuous variables) for each year. Chi-square tests were used to 
study time (year) effects on differences in patient characteristics across time.
To study the dynamics of longitudinal trends in the outcomes of interest, we adapted and 
extended a two-step join-point Poisson regression modeling approach(17) by fitting a series 
of straight lines on a log scale to the trend; each join-point represents a statistically 
significant (p<0.05) change in trend (i.e., slope of the line segment). For example, a single 
join-point splits the trend line into two line segments, whereas zero join-points indicates that 
the best fit to the trend consists of only a single line segment. In the first step, we identified 
the optimal join-point(s) using a nonlinear modeling approach. Next, multivariable analyses 
were performed based on the selected join-point(s) as well as potential stratification 
variables. Interactions were tested only for individual variables that were significant. 
Variables were retained in the final model if estimated annual percentage changes (APCs) 
before and after the join-point were significant (p<0.05). We also evaluated whether the 
APC of each line segment differed from no change (APC=0). For each outcome of interest, 
we estimated adjusted APCs (aAPC) and 95% confidence intervals (CI), as well as adjusted 
prevalence rates by year or by age, race, or sex. Study sites were included in all analysis as 
the stratification variable.
We did not use age-standardized rates in the model to avoid masking the known birth-cohort 
effect in HCV patients born between 1945 and 1965(8); this is consistent with the approach 
used in a recent study of cirrhosis prevalence among US veterans (18). However, age was 
included as a stratification variable. SAS Version 9.4 (SAS Institute Inc, Cary NC) was used 
for all analyses.
RESULTS
We identified 11,167 confirmed HCV patients with 80,988 person-years of observation 
across the 2006–2015 study period, with 3856 cases of prevalent cirrhosis (34.5% 
cumulative, including decompensated), 2027 cases of prevalent decompensated cirrhosis 
(18.2% cumulative), and 2246 incident deaths (20.1%). Among the 11,167 patients, 8185 
had their initial HCV diagnosis prior to or during 2006, while the remaining 2982 were 
newly diagnosed during the study period. The cohort size varied across time—from 8185 in 
2006, to 6100 in 2015—due to the addition of incident HCV cases and the loss of patients 
who died or left the health systems. Among 2027 patients with decompensated cirrhosis, 
30% had diagnosis or procedure codes related to liver transplant in the EHR; 39% had codes 
related to hepatocellular carcinoma (HCC); 23% had codes related to encephalopathy; 65% 
had codes related to ascites; and those symptoms were not mutually exclusive. Among 2246 
HVC patients who died from 2006–2015, reports of liver-related death varied from year to 
year, ranging from 39% to 46%, with data missing for an additional 7–10% annually.
Select patient demographics are presented in Table 1. Notably, our cohort aged significantly 
over time. In 2006, only 14% of patients were >60 years old; this proportion increased to 
49% by 2014. Likewise, the proportion of female patients increased from 40% to 43% over 
the same time period. The overall unadjusted prevalence of cirrhosis, decompensated 
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cirrhosis, and incidence of all-cause mortality is illustrated in Figure 1. There were three 
treatment eras during this ten year period, which are indicated in Figure 1: the ribavirin + 
interferon combination therapy era (2006–2010); the triple therapy era (2011–2013), and the 
DAA era (2014–2015). Annual rates of HCV treatment were low, but increased from less 
than 5% in 2006 to roughly 15% in 2015. We did note increased rates of treatment among 
cirrhotic patients (from 23% in 2006 to 53% in 2015).
Prevalence of cirrhosis
Prevalence of cirrhosis (including decompensated cirrhosis) increased from 20.8% (in 2006) 
to 27.6% (in 2015), with no join-point identified. The overall adjusted APCs (aAPC, 
adjusted for race, sex, and age category, Figure 2) was 1.2 (p<0.01). We did not find any 
interactions between time and covariates (age, sex or age), indicating that—although each 
factor independently impacted prevalence rates—their effect was consistent over time. 
Notably, both Black/African American and AAPI patients demonstrated significantly higher 
prevalence of cirrhosis than White patients (p<0.01). Older patients (especially those ≥60) 
and men also demonstrated significantly higher prevalence than younger patients or women, 
respectively. Consistent with the overall results, increases in cirrhosis rates among these 
groups were consistent over time.
Prevalence of decompensated cirrhosis
The model for prevalence of decompensated cirrhosis also fitted to a straight line (no join-
points) with APC of 1.5 (p<0.01), indicating that the increase from 9.3% (in 2006) to 10.4% 
(in 2015) was consistent across the study period. However, the multivariate analysis showed 
a significant interaction between age and time; this indicates that the trend (APC) varied 
across age groups. We found that higher prevalence and increasing trends were both 
confined to patients ≥60 (aAPC=1.5, p=0.023). Lower prevalence and declining trends were 
observed in patients 40–<50 and 50–<60 (aAPCs=−3.2 and −7.9, respectively; p<0.01 for 
both); no change was observed among patients <40 (Figure 3). Men demonstrated higher 
prevalence of decompensated cirrhosis than women, while higher rates of decompensated 
cirrhosis were found in Black/African American and AAPI patients than White patients 
(p<0.01).
Incidence of all-cause mortality
Overall incidence of all-cause mortality increased across the study period, from 1.8% (in 
2006) to 2.9% (in 2015). However, this increase was confined almost entirely to the period 
prior to the 2010 join-point (Figure 1, Table 2). APCs were 13.7 and −1.6 (p<0.01 and 0.28) 
before and after 2010, respectively; aAPCs were 9.6 and −5.2 (p<0.01 for both), indicating 
that there was a significant decrease in incidence of all-cause mortality after 2010. We 
observed that age, sex contributed independently to incidence of mortality (Figure 4), but 
trends remained consistent across time among groups. Older patients (especially those ≥60) 
and men again demonstrated the highest incidence of mortality (Figure 4). Despite higher 
rates of cirrhosis among Black/African American and AAPI patients compared to White, 
there was no significant difference in mortality by race (p=0.13).
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DISCUSSION
Consistent with recent studies, we found a marked increase in cirrhosis prevalence from 
2006 to 2015 in a diverse, non-veteran-based cohort of over 11,000 HCV patients. Likewise, 
even though the overall rate of all-cause mortality roughly doubled from 2006 to 2010, 
incidence declined after 2010. Trends in prevalence of decompensated cirrhosis varied by 
age; although prevalence increased significantly in patients ≥ 60 years old, rates plateaued or 
declined among younger age groups.
Our observation of increasing prevalence of cirrhosis but decreasing rates of decompensated 
cirrhosis and all-cause mortality suggests that cirrhotic patients are living longer. This may 
be a result of more frequent antiviral treatment among cirrhotic patients (we observed an 
increase from 22% in 2006 to 53% in 2015), reducing the number of patients who progress 
to decompensated cirrhosis and death. Although there is some evidence that liver fibrosis 
may regress after SVR, we cannot adequately capture this regression. Being conservative, 
we considered cirrhosis to persist in the absence of a liver transplant,
We found significant disparities in the prevalence of HCV-related complications across age, 
sex, and racial categories. HCV patients ≥60 years old had the highest prevalence of liver-
related complications and all-cause mortality; similar findings have been reported among US 
veterans (19). Sex also independently influenced all outcomes (Figures 2–4), although to a 
lesser extent than age. Men had the highest prevalence of cirrhosis and decompensated 
cirrhosis, as well as incidence of mortality.
We observed that decompensated cirrhosis increased only 1 percentage point in 10 years, 
and only among patients in the oldest age group (≥60), despite larger increases in the 
prevalence of cirrhosis across all age groups. We speculate that this may be due to 
improvements in HCV treatment, particularly among patients with advanced fibrosis (6, 20). 
Although we observed an overall increase in the incidence of all cause-mortality (from 1.8% 
in 2006 to 2.9% in 2015), our analyses indicated that the rate of increase reversed after 2010; 
this may also be related to better HCV treatment options as well as improved survival in 
patients with late-stage liver disease(21, 22).
Notably, Black/African American patients in our cohort demonstrated the highest prevalence 
of cirrhosis, even after controlling for age. This finding is in contrast to studies that have 
found lower risk of cirrhosis among Black patients with HCV (23–25). A number of 
previous studies have shown that Black/African Americans were historically less likely to 
receive interferon-based HCV treatment (26–29); our own recent study of the factors 
associated with DAA uptake has demonstrated the same pattern (30). The higher prevalence 
of cirrhosis observed in this racial group may be related to differences in receipt of therapy 
or access to care. Future studies investigating the causes of these disparities are warranted.
Our study has several limitations. We used all-cause mortality instead of HCV-related 
mortality because a previous CHeCS analysis demonstrated that liver-related mortality is 
under-reported in routine-care settings(16). Although our analysis is based on ongoing 
“dynamic” cohort accrual from health system populations, the cohort has aged significantly 
over time; patients ≥60 years made up only 15% of our 2006 cohort, but more than a half 
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(53%) of the cohort in 2015. However, we tested for interactions between age and time 
trends. Likewise, we did not adjust for the effect of treatment or SVR on these trends 
because our analysis was designed to describe overall temporal changes HCV-related 
complications, rather than individual treatment effect on a patient’s trajectory, which has 
been studied thoroughly for interferon-based treatment (6, 20). It would not be appropriate 
to assess treatment effect in the present trend analysis, because HCV treatment-related 
factors, including eligibility for treatment/treatment uptake, treatment failure (especially for 
interferon-based treatment), treatment response (SVR) and the rate of SVR responses, are a 
function of the era of HCV treatment. Nevertheless treatment impact may be minimal in the 
present trend analysis given low HCV treatment uptake and SVR responses in this 
population.
Because our cohort consists of individuals with at least some contact with the health system, 
we are unable to estimate the prevalence of outcomes in HCV-positive individuals who 
remain undiagnosed or those without ongoing contact with a health care system. Such 
individuals are perhaps most at risk for poor outcomes. In addition, our study is based 
primarily upon health records data and may fail to capture factors that potentially affect 
clinical outcomes, such as disease duration or undiagnosed substance or alcohol abuse. Our 
study is also limited generally to the era of interferon-based therapy through the introduction 
of triple therapy that included the initial protease inhibitors boceprevir and telaprevir.
In conclusion, although overall prevalence of cirrhosis increased by roughly 40% among 
HCV-infected patients in the US, all-cause mortality declined significantly in recent years. 
Likewise, increasing prevalence of decompensated cirrhosis was confined to patients over 
60. Accelerating uptake of highly effective direct-acting all-oral regimens may ultimately 
reverse the increase of liver-related complications in this population.
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Abbreviations
HCV hepatitis C virus
CHeCS The Chronic Hepatitis Cohort Study
APC annual percentage change
aAPC adjusted annual percentage change
NHANES National Health and Nutrition Examination Survey
ICD9 International Classification of Diseases, 9th edition
HBV hepatitis B virus
HIV human immunodeficiency virus
FIB4 Fibrosis-4 Index
AUROC area under the receiver operating characteristic curve
PPV positive predictive value
CART Classification and Regression Tree
AAPI Asian American or Pacific Islander
CI confidence interval
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Key Points
• We applied join-point modeling to data from the Chronic Hepatitis Cohort 
Study to study changing trends in rates of cirrhosis, decompensated cirrhosis, 
and all-cause mortality among a geographically- and racially-diverse sample 
of over 11,000 hepatitis C patients
• Increasing prevalence of cirrhosis and mortality in HCV patients has slowed 
down or leveled off in recent years
• Increasing prevalence of decompensated cirrhosis is confined to patients over 
60
• African Americans and Asian Americans demonstrate higher rates of 
cirrhosis than White patients
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Figure 1. 
Prevalence of cirrhosis and decompensated cirrhosis, and incidence of all-cause mortality in 
CHeCS HCV patients from 2006–2015 (join-points for all-cause mortality in 2010).
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Figure 2. 
Prevalence of cirrhosis by race, sex, and age in CHeCS HCV patients from 2006–2015. No 
join-points and only one segment were identified. Line segments illustrate the adjusted 
annual percent change (aAPC).
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Figure 3. 
Prevalence of decompensated cirrhosis by race, sex, and age in CHeCS HCV patients from 
2006–2015. No join-points and only one segment were identified. Line segments illustrate 
the adjusted annual percent change (aAPC).
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Figure 4. 
Incidence of all-cause mortality by sex and age in CHeCS HCV patients from 2006–2015. 
One join-point (2010) and two segments were identified. Line segments illustrate the 
adjusted annual percent change (aAPC).
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Table 2
Unadjusted and adjusted annual percentage change and join-points for hepatitis C-related outcomes.
Annual percentage change (APC)
First segment Second segment
Interval Interval
APC (95%CI) p-value APC (95%CI) p-value
Cirrhosis 2006≤2015
 Unadjusted 2.7 (2.1, 3.2) <0.01
 Adjusted 1.2 (0.7, 1.8) <0.01
Decompensated Cirrhosis 2006≤2015
 Unadjusted 1.5 (0.7, 2.4) <0.01
 Adjusted (<40) −3.7 (−11.9, 5.3) 0.40
 Adjusted (40<50) −7.9 (−10.9, −4.8) <.0001
 Adjusted (50<60) −3.2 (−4.4, −1.9) <.0001
 Adjusted (≥60) 1.5 (0.2, 2.8) 0.02
All-cause Mortality 2006<2010 2010≤2015
 Unadjusted 13.7 (9.4, 18.1) <0.01 −1.6 (−4.4, 1.3) 0.28
 Adjusted 9.6 (5.5, 13.8) <0.01 −5.2 (−7.9, −2.4) <0.01
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